Elotuzumab
AbbVie,BMS
['mmsm']
#asco23 #mmsm 15.4% had iss iii 108/459 (23.5%) had high-risk cytogenetics (del[17p]; t[4;14]; t[14;16]; 3 1q21 copies) this is concerning since we don t know cytogenetics in 120 pts (~21% of enrolled pts) an issue we published: 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities